Bone Marrow Donors Can Be Hard to Find. One Company Is Turning to Cadavers
San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...
FierceBiotech5h
Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge
The response rate in the control cohort is in line with historical data on azacitidine. Investors, already burnt by setbacks ...
IN8bio, Inc: IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...
Promising Market Potential and Efficacy of Syndax Pharmaceuticals’ Revumenib Justify Buy Rating
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...
The Pharma Letter15h
Syndax shares slide despite pivotal trial success
The study is testing the drug in certain patients with relapsed or refractory acute myeloid leukemia (AML). The small ...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
Oncology Nurse Advisor20h
HSCT From Deceased Donors: A New Frontier?
A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Medical Xpress23h
Treatment target for aggressive leukemia discovered by disrupting its genome organization
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...